Premium
TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY
Author(s) -
Kaplan J.,
Gordon L.,
Infante J.,
Popat R.,
Rambaldi A.,
Madan S.,
Patel M.R.,
Gritti G.,
ElSharkawi D.,
Chau I.,
Radford J.,
Perez De Oteyza J.,
Zinzani P.,
Iyer S.,
Faucette S.,
SheldonWaniga E.,
Stumpo K.,
Shou Y.,
Carpio C.,
Bosch F.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_60
Subject(s) - syk , medicine , lymphoma , adverse effect , follicular lymphoma , neutropenia , chronic lymphocytic leukemia , oncology , leukemia , cancer research , tyrosine kinase , toxicity , receptor